Merck & Co. Inc. (MRK): Price and Financial Metrics

Merck & Co. Inc. (MRK): $102.95

1.35 (-1.29%)

POWR Rating

Component Grades








MRK Price/Volume Stats

Current price $102.95 52-week high $119.65
Prev. close $104.30 52-week low $86.02
Day low $102.71 Volume 7,232,700
Day high $104.68 Avg. volume 7,549,386
50-day MA $107.52 Dividend yield 2.81%
200-day MA $109.82 Market Cap 261.24B

MRK Stock Price Chart Interactive Chart >


  • MRK scores best on the Stability dimension, with a Stability rank ahead of 84.15% of US stocks.
  • MRK's strongest trending metric is Quality; it's been moving down over the last 177 days.
  • MRK's current lowest rank is in the Momentum metric (where it is better than 9.63% of US stocks).

MRK Stock Summary

  • MRK has a market capitalization of $269,840,001,111 -- more than approximately 99.45% of US stocks.
  • MRK's current price/earnings ratio is 86.74, which is higher than 94.12% of US stocks with positive earnings.
  • The volatility of MERCK & CO INC's share price is greater than that of merely 0.86% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to MRK, based on their financial statements, market capitalization, and price volatility, are ASML, INTC, ABBV, AVGO, and PFE.
  • Visit MRK's SEC page to see the company's official filings. To visit the company's web site, go to

MRK Valuation Summary

  • MRK's EV/EBIT ratio is 47.1; this is 306.03% higher than that of the median Healthcare stock.
  • MRK's EV/EBIT ratio has moved up 35.8 over the prior 243 months.

Below are key valuation metrics over time for MRK.

Stock Date P/S P/B P/E EV/EBIT
MRK 2023-09-22 4.6 7.0 86.7 47.1
MRK 2023-09-21 4.6 7.0 87.1 47.2
MRK 2023-09-20 4.7 7.0 87.5 47.5
MRK 2023-09-19 4.7 7.0 87.6 47.5
MRK 2023-09-18 4.7 7.1 87.9 47.7
MRK 2023-09-15 4.7 7.1 87.7 47.5

MRK Growth Metrics

    The 3 year net income to common stockholders growth rate now stands at 68.83%.
  • Its 4 year net income to common stockholders growth rate is now at 133.51%.
  • The year over year cash and equivalents growth rate now stands at 22.56%.
MRK's revenue has moved up $10,426,000,000 over the prior 15 months.

The table below shows MRK's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 58,974 19,696 15,260
2022-06-30 57,169 18,891 16,579
2022-03-31 53,978 17,079 14,180
2021-12-31 48,704 14,109 13,049
2021-09-30 49,151 13,084 7,197
2021-06-30 48,548 10,460 5,571

MRK's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRK has a Quality Grade of B, ranking ahead of 77.57% of graded US stocks.
  • MRK's asset turnover comes in at 0.535 -- ranking 75th of 682 Pharmaceutical Products stocks.
  • XTNT, ACOR, and BDSI are the stocks whose asset turnover ratios are most correlated with MRK.

The table below shows MRK's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.535 0.675 0.129
2021-03-31 0.529 0.670 0.158
2020-12-31 0.538 0.677 0.171
2020-09-30 0.542 0.712 0.276
2020-06-30 0.550 0.701 0.260
2020-03-31 0.571 0.701 0.256

MRK Price Target

For more insight on analysts targets of MRK, see our MRK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $93.38 Average Broker Recommendation 1.52 (Moderate Buy)

Merck & Co. Inc. (MRK) Company Bio

Merck & Co., Inc.d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891.(Source:Wikipedia)

MRK Latest News Stream

Event/Time News Detail
Loading, please wait...

MRK Latest Social Stream

Loading social stream, please wait...

View Full MRK Social Stream

Latest MRK News From Around the Web

Below are the latest news stories about MERCK & CO INC that investors may wish to consider to help them evaluate MRK as an investment opportunity.

Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies

Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.

Yahoo | September 25, 2023

10 Best Ways to Prevent Type 2 Diabetes

In this article, we shall discuss the 10 best ways to prevent type 2 diabetes. To skip our detailed analysis of the global diabetes industry and the larger pharmaceutical industry in 2023, go directly and see 5 Best Ways to Prevent Type 2 Diabetes. Diabetes is directly responsible for more than 280,000 deaths each year. […]

Yahoo | September 25, 2023

20 Most Innovative Companies in America

In this article, we will take a look at the most innovative companies in America. If you want to explore similar companies, you can go to 5 Most Innovative Companies in America. Innovation and American Companies Innovation comes with new and creative ideas that bring a healthy change in society. Innovation in business and technology […]

Yahoo | September 22, 2023

Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

RAHWAY, N.J., September 22, 2023--Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of OS & PFS in Certain Patients With Previously Untreated la/m UC

Yahoo | September 22, 2023

Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag

The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.

Yahoo | September 21, 2023

Read More 'MRK' Stories Here

MRK Price Returns

1-mo -4.89%
3-mo -10.17%
6-mo -4.16%
1-year 22.81%
3-year 36.56%
5-year 67.69%
YTD -5.30%
2022 49.42%
2021 -2.91%
2020 -7.20%
2019 22.27%
2018 39.95%

MRK Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full MRK Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!